Subantibiotic dose of azithromycin attenuates alveolar bone destruction and improves trabecular microarchitectures in a rat model of experimental periodontitis: A study using micro-computed tomography

Rossomando, 1990, Tumor necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans, Arch. Oral Biol., 35, 431, 10.1016/0003-9969(90)90205-O Mogi, 1999, Interleukin 1β, interleukin 6, β2-microglobulin, and transforming growth factor-α in gingival crevicular fluid from human periodontal disease, Arch. Oral Biol., 44, 535, 10.1016/S0003-9969(99)00020-5 Tatakis, 1993, Interleukin-1 and bone metabolism: a review, J. Periodontol., 64, 416 Kobayashi, 2000, Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction, J. Exp. Med., 191, 275, 10.1084/jem.191.2.275 Liu, 2005, Cross-talk between the interleukin-6 and prostaglandin E2 signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of NF-κB (RANK) ligand/RANK system, Endocrinology, 146, 1991, 10.1210/en.2004-1167 Preshaw, 2008, Host response modulation in periodontics, Periodontol. 2000, 48, 92, 10.1111/j.1600-0757.2008.00252.x Zuckerman, 2009, Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline, Infect. Dis. Clin. N. Am., 23, 997, 10.1016/j.idc.2009.06.013 Culić, 2001, Anti-inflammatory effects of macrolide antibiotics, Eur. J. Pharmacol., 429, 209, 10.1016/S0014-2999(01)01321-8 Rubin, 2004, Immunomodulatory properties of macrolides: overview and historical perspective, Am. J. Med., 117, 2S Suzaki, 1999, Suppressive activity of a macrolide antibiotic, roxithromycin, on proinflammatory cytokine production in vitro and in vivo, Mediators Inflamm., 8, 199, 10.1080/09629359990351 Shinkai, 2006, Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GMCSF production by human bronchial epithelial cells, Am. J. Physiol. Lung Cell. Mol. Physiol., 290, L75, 10.1152/ajplung.00093.2005 Retsema, 1987, Spectrum and mode of action of azithyromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms, Antimicrob. Agents Chemother., 31, 1939, 10.1128/AAC.31.12.1939 Sampaio, 2011, Clinical and microbiological effects of azithromycin in the treatment of generalized chronic periodontitis: a randomized placebo-controlled clinical trial, J. Clin. Periodontol., 38, 838, 10.1111/j.1600-051X.2011.01766.x Hirsch, 2012, Azithromycin in periodontal treatment: more than an antibiotic, J. Periodontal Res., 47, 137, 10.1111/j.1600-0765.2011.01418.x Meyer, 2009, Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis, Am. J. Respir. Cell Mol. Biol., 41, 590, 10.1165/rcmb.2008-0155OC Choi, 2014, Effect of azithromycin on Prevotella intermedia lipopolysaccharide-induced production of interleukin-6 in murine macrophages, Eur. J. Pharmacol., 729, 10, 10.1016/j.ejphar.2014.02.008 Bae, 2016, Effects of daidzein on alveolar bone loss and internal microstructures of bone in a rat model of experimental periodontitis: a study using micro-computed tomography, J. Periodontal Res., 51, 250, 10.1111/jre.12304 Luan, 2008, Inhibition of experimental periodontitis by a topical boron-based antimicrobial, J. Dent. Res., 87, 148, 10.1177/154405910808700208 Bouxsein, 2010, Guidelines for assessment of bone microstructure in rodents using micro-computed tomography, J. Bone Miner. Res., 25, 1468, 10.1002/jbmr.141 Kudoh, 1998, Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin, Am. J. Respir. Crit. Care Med., 157, 1829, 10.1164/ajrccm.157.6.9710075 Yamaya, 2012, Macrolide effects on the prevention of COPD exacerbations, Eur. Respir. J., 40, 485, 10.1183/09031936.00208011 Samson, 2016, Long-term effects of azithromycin in patients with cystic fibrosis, Respir. Med., 117, 1, 10.1016/j.rmed.2016.05.025 Wan, 2015, Azithromycin attenuates pulmonary inflammation and emphysema in smoking-induced COPD model in rats, Respir. Care, 60, 128, 10.4187/respcare.03344 Mahgoub, 2005, Azithromycin and erythromycin ameliorate the extent of colonic damage induced by acetic acid in rats, Toxicol. Appl. Pharmacol., 205, 43, 10.1016/j.taap.2004.09.012 de Lima, 2000, Effects of chlorpromazine on alveolar bone loss in experimental periodontal disease in rats, Eur. J. Oral Sci., 108, 123, 10.1034/j.1600-0722.2000.00766.x Di Paola, 2004, Effect of aminoguanidine in ligature-induced periodontitis in rats, J. Dent. Res., 83, 343, 10.1177/154405910408300414 Park, 2007, Three-dimensional micro-computed tomographic imaging of alveolar bone in experimental bone loss or repair, J. Periodontol., 78, 273, 10.1902/jop.2007.060252 Wuyts, 2010, Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model, Exp. Lung Res., 36, 602, 10.3109/01902148.2010.492895 Yamada, 2013, Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii, Antimicrob. Agents Chemother., 57, 3883, 10.1128/AAC.00457-13 Bin, 2000, Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice, Antimicrob. Agents Chemother., 44, 1761, 10.1128/AAC.44.6.1761-1764.2000 Hoffmann, 2007, Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr−/− mice, Antimicrob. Agents Chemother., 51, 3677, 10.1128/AAC.01011-06 Conte, 1996, Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects, Antimicrob. Agents Chemother., 40, 1617, 10.1128/AAC.40.7.1617 Khan, 1999, Effect of clarithromycin and azithromycin on production of cytokines by human monocytes, Int. J. Antimicrob. Agents, 11, 121, 10.1016/S0924-8579(98)00091-0 Gannon, 2013, Azithromycin suppresses human osteoclast formation and activity in vitro, J. Cell. Physiol., 228, 1098, 10.1002/jcp.24259 Hirsch, 2010, Periodontal healing and bone regeneration in response to azithromycin, Aust. Dent. J., 55, 193, 10.1111/j.1834-7819.2010.01227.x Ren, 2004, Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-κB activity, J. Orthop. Res., 22, 21, 10.1016/S0736-0266(03)00130-X